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ABSTRACT
As part of the intracellular processes leading to mast cell and basophil activation, phosphorylation of key
substrates is likely to be important. These processes, mediated by phosphatases, are responsible for regu-
lating phosphorylation. The aim of the present study was to determine effects fostriecin – a selective
inhibitor of PP2A (protein phosphatase-2) – on b2-adrenoceptor-driven responses in human mast cells.
Here, the effects of fostriecin (PP inhibitors) on the inhibition of histamine release from HLMC, on b-adre-
noceptor-driven responses in mast cells and on desensitization were investigated. Long-term incubation
(24 h) of mast cells with fostriecin (106 M) resulted in a significant (p < 0.001) reduction in the maximal
response (from 41.2 [± 3.0] to 29.9 [± 4.2] %) to salbutamol following fostriecin treatment. The results
showed that fostriecin pretreatment significantly attenuated the inhibitory effects of salbutamol. Overall,
the present study suggested that PP2A has an important role in regulating mast cell b2-adrenoceptors.
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Introduction
In the past decade, there has been a considerable increase in
attempts to clarify the biological roles of protein phosphatases,
and their potential importance in the context of health and dis-
ease (Yu et al. 2016). Protein phosphatases that dephosphorylate
either tyrosine or serine and threonine constitute the two main
families and are referred to as protein tyrosine phosphatases
(PTP) and protein serine/threonine phosphatase (PP), respect-
ively (Cohen et al. 1991). Protein tyrosine phosphatases form a
large family of still largely uncharacterized enzymes (Kuropka
et al. 2016). The level of tyrosine phosphorylation in normal cells
is determined by the balanced activity of protein tyrosine kinases
(PTK) and PTP. It was previously shown that the adrenoceptors
expressed by human lung mast cells (HLMC) and that mediate
inhibition of mediator release are b2-adrenoceptors and that
these receptors may be readily desensitized (Chong et al. 2002).
Decreased responsivity to stimulation arises with most cell
surface receptors when exposed to an agonist. Short-term expos-
ure (few seconds) to b2-adrenoceptor agonists results in receptor
phosphorylation by both cAMP-dependent protein kinase A
(PKA) and G-protein receptor kinase (GRK), whereas long-term
exposure to b2-adrenoceptor agonists includes downregulation of
surface receptor numbers (which involves internalization and
degradation of the receptors; Carter & Hill, 2005) and results in
changes in the transcription of b-adrenoceptors or mRNA stabil-
ity (Yanagawa et al. 2016). A reduction in b2-adrenoceptor
mRNA after incubation with b2-adrenoreceptor agonists are con-
sistent with decreased synthesis of b2-adrenoceptors after pro-
longed agonist contact; this amount is independent of continued
occupation of b2-adrenoceptors on the cell surface (Chong et al.
2003). Studies indicated that GRK-catalyzed phosphorylation of
G-protein-coupled receptors (GPCR) followed by b-arrestin bind-
ing are key steps in the internalization of receptors or in
receptor desensitization. Based on those findings, b-arrestin over-
expression promoted sequestration of the b2-adrenergic receptor
(Sibley et al. 1986). This, in turn, suggested that b2-adrenergic
receptor internalization played a key role in receptor dephos-
phorylation and resensitization. It has been termed the GPCR
phosphatase (PP) and at least in vitro, is active against not only
the GRK-phosphorylated b2-adrenergic receptor but also the a2-
adrenergic receptor and rhodopsin.
Previous work from our laboratory has shown that long-term
exposure of HLMC to b-agonists attenuated the subsequent ability
of the agonists to inhibit histamine release (Chong et al. 2003;
Bastan et al. 2014). As phosphorylation of b2-adrenoceptors is per-
haps essential in inducing desensitization in many cells, including
mast cells, this study sought to investigate the importance of phos-
phorylation events in mast cells by targeting some of their protein
phosphatases. Specifically, the main aim here was to investigate
effects of fostriecin a selective inhibitor of PP2A – on b2-adreno-
ceptor-driven responses in human mast cells in vitro. Comparisons
of effects from fostriecin with those from okadaic acid, an inhibitor
of PP2A (protein phosphatase-2) and PP1 (protein phosphatase-1),
on the functional desensitization of b-adrenoceptor-mediated
responses in mast cells in vitro were also investigated.
Materials and methods
Buffers
Phosphate-buffered saline (PBS) containing 137mM NaCl, 8mM
Na2HPO4, 2.7mM KCl and 1.5mM KH2PO4 was used in these
studies. PBS-bovine serum albumin (BSA) was PBS also contain-
ing 1mM CaCl2, 1mM MgCl2, 5.6mM glucose, 1mg BSA/mL
and 15 lg DNase/mL. PBS-human serum albumin (HSA) was
PBS additionally supplemented with 1mM CaCl2, 1mM MgCl2,
5.6mM glucose and 30 lg HSA/ml. The pH of all PBS buffers
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was 7.3. All materials for the buffers were purchased from Sigma
(Poole, UK).
Preparation of inhibitors and stimuli
Protein phosphatase inhibitor isoprenaline was made up as a
10mM stock in 0.05% (w/v) sodium metabisulfite (in normal
saline). Okadaic acid was made up as a 0.5mM stock in 10%
dimethyl sulfoxide (DMSO). Fostriecin was made up as 1mM
solutions in 10% and 100% methanol. Salbutamol was prepared
as a 10mM stock in distilled water. All materials for the inhibi-
tors were purchased from Sigma (Poole, UK). Each drug was
diluted to desired levels in buffer just before use.
The stimulus used in mediator release experiments was poly-
clonal goat anti-human IgE prepared according to manufacturer’s
instructions (Sigma Chemical Co., Poole, UK). The lyophilized
powder was reconstituted in 2mL ultra-pure H2O and the solu-
tions were stored at 20 C. Preliminary experiments indicated
the vehicles used to prepare the drugs had no effect on histamine
release or on the protein PP assays.
Isolation of human lung mast cells (HLMC)
Mast cells (HLMC) were isolated from human lung tissue using
the method of Ali and Pearce (1985). In brief, the lung tissue
was obtained from surgical resections of patients were under-
going surgery for carcinoma. All patients gave written informed
consent. None had overt pulmonary inflammatory diseases such
as sarcoidosis, tuberculosis, etc. at the time of sample collection.
There were an equal number of males and females from whom
samples were obtained. All of these protocols had received the
approval of the Local Research Ethics Committee.
In each case, macroscopically-normal tissue (10–40 g) was
excised at least 2 cm from the tumor. Each tissue sample was
chopped vigorously for 10min in a small volume of PBS buffer
and then washed through a nylon mesh (100 lm pore size;
Incamesh, Warrington, UK) with PBS buffer. The tissue was then
placed in PBS-BSA (10mL/g tissue) containing Collagenase Ia
(0.1mg/mL; Sigma) and placed in a 37 C water bath. After
90min with constant stirring, the mixture (containing some mast
cells) was separated from nondigested tissue by filtration through
100-lm pore nylon mesh. The filtrate was then diluted with
PBS-BSA buffer and further dissociated with a syringe. The mix-
ture was then passed again over 100-lm nylon mesh. After col-
lection, all filtrates were pooled, centrifuged (120 g, 8min,
25 C), and the final pellet reconstituted in PBS-BSA. Cells were
counted with a hemocytometer; mast cells were visualized by
removing aliquots and staining subsequently prepared slide with
Alcian blue stain (Gilbert & Ornstein, 1975). Based on these
analyses, HLMC levels in the preparations were calculated. Of
the total cells, 3–13% were mast cells. This method routinely
yielded 2–9 105 mast cells/g tissue HLMC for use in the hista-
mine release experiments.
Mediator release
Mediator release experiments were performed in PBS-HSA
buffer. Mast cells were incubated with or without an immuno-
suppressant for 5min, unless otherwise indicated in the text,
before the challenge with stimulus. Preliminary experiments indi-
cated that extending the incubation time from 5–60min did not
alter inhibitory effects of the drugs. Mediator release was initiated
immunologically with anti-IgE. Concentrations of anti-IgE were
chosen that elicited 30% of total histamine content from the
cell preparations. In HLMC, this was a fixed concentration
(1:300) of anti-IgE. Stimulus-induced secretion was allowed to
proceed for 25min at 37 C after which the cells were pelleted by
centrifugation (400 g, 25 C, 4min). Histamine released into
supernatant was determined using the automated fluorometric
assay of Siraganian (1974). Total histamine content was deter-
mined by lysing aliquots of cells (i.e. 20,000 mast cells/sample)
with 1.6% perchloric acid for 25min at 37 C. Cells incubated in
buffer alone served as a measure of spontaneous histamine
release [which ranged from 2–8% of total histamine content].
None of the drugs used in this study influenced spontaneous his-
tamine release (data not shown; pilot study). Histamine release
was expressed as a percentage of total histamine content after
subtracting for spontaneous histamine release. All assays were
performed in duplicate.
Statistical analysis
Data are expressed as means ± SEM. Maximal responses (Emax)
and potencies (pEC50) by nonlinear regression analysis were
determined using by Prism software (GraphPad, San Diego, CA).
Nonlinear regression was used to generate a line or a curve, as if
every value of Y was a random variable, and also used logarith-
mic functions. To determine if there was any difference in
responses after treatments with drugs, repeated measures analysis
of variance was performed. To establish whether drug treatments
caused statistically significant effects, either paired t-tests or a
two-way analysis of variance (ANOVA) followed by a Dunnett's
test was performed. A p values <.05 was accepted as significant.
Results
Effects of PP inhibitors on IgE-mediated histamine release
Effects of PP inhibitors on inhibition of histamine release from
HLMC incubated (2 h) with increasing concentrations of fostrie-
cin or okadaic acid (OA) and then exposed to anti-IgE to induce
histamine release was assessed. Fostriecin (109–106 M) failed
to affect the histamine release from the mast cells, whereas OA
(1010–106 M) effectively inhibited histamine release (i.e.
from 20% vs. control at 1010–10 8 M to >80% versus control
at 10 6 M) (Figure 1).
Effects of PP inhibitors on mast cell b-agonists
To evaluate the effects of fostriecin on isoprenaline inhibition,
cells were incubated for 2, 4 or 24 h (Figure 2) with fostriecin
(106 M) before incubation with isoprenaline (1010–10 5 M)
and then challenged by anti-IgE. Treatments with fostriecin had
no significant effect on either the efficacy or the potency of
isoprenaline.
In a similar set of experiments, the inhibitory response of
HLMC to salbutamol, after a 4-h treatment with fostriecin was
investigated. Salbutamol inhibition of histamine release was not
affected to a significant degree after treatment with fostriecin.
However, after a longer (24 h) incubation of the mast cells with
fostriecin (106 M), there was a significant (p < .001) reduction
in maximal response (from 41.2 [± 3.0] to 29.9 [± 4.2]%) to sal-
butamol following fostriecin treatment (Figure 3).
The effect of OA on b-agonist inhibition of histamine release
from HLMC was also investigated (data not shown). Cells were
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incubated (24 h) either with buffer or OA (3 108 M) before
incubation with isoprenaline (1010–105 M) and then chal-
lenged by anti-IgE (1:300). Longer (24 h) treatment with OA at
this low concentration had no effect on inhibition of histamine
release by isoprenaline.
Effect of PP inhibitors on desensitization
To evaluate whether desensitization induced by b-agonists could
be influenced by fostriecin, HLMC were treated with either buf-
fer or fostriecin (106 M) and with/without isoprenaline
(106 M) for 24 h (Figure 4). Isoprenaline (106 M) pretreat-
ment reduced maximal responses to 1010–106 M isoprenaline
(prior to anti-IgE stimulation) by almost>50% (vs. level seen in
cells pretreated with buffer, that is, 46 ± 2% inhibition versus
release from control cells that only saw anti-IgE) across nearly all
the re-treatment doses. Fostriecin pretreatment alone (106 M)
had little effect on functional desensitization with levels lower
(albeit not significant) than levels of inhibition seen with buffer
pretreated cells across nearly all the doses of isoprenaline used
pre-anti-IgE. Effects from the combined pretreatment with fos-
triecin and isoprenaline yielded inhibition levels nearly midway
between those of either agent alone. Effects of OA (3 108 M)
on desensitization were also investigated (data not shown).
Though 24-h pretreatments with OA had no effect on the ability
of isoprenaline to inhibit histamine release, it significantly
enhanced the extent of isoprenaline-induced desensitization (data
not shown).
In another series of assays, HLMC were treated with buffer or
fostriecin (106 M) and with/without salbutamol (106 M) for
24 h (Figure 5) before salbutamol (1010–105 M) retreatment
for 10min and then challenge with anti-IgE (1:300) to induce
histamine release. As expected, salbutamol pretreatment signifi-
cantly (p < .001) reduced subsequent inhibition of histamine
release from mast cells by salbutamol (i.e. vs. cells that had been
pretreated with buffer; maximal inhibition in the latter
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Figure 1. Effect of fostriecin and okadaic acid on histamine release from HLMC.
Cells were incubated for 2 h with increasing concentrations of fostriecin or oka-
daic acid (OA) before challenge with an optimal releasing concentration of anti-
IgE (1:300) for a further 25min to induce histamine release. Results are expressed
as the percent inhibition of the control histamine release values which were 27
[± 3]% (in fostriecin studies) and 35 [± 4]% (in OA studies). Significant inhibition
versus control. Values shown are means ± SEM, n¼ 4/regimen (fostriecin) and
n¼ 12/regimen (OA).
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Figure 2. Effect of fostriecin on isoprenaline inhibition of histamine release from
HLMC. Cells were incubated without (square) or with fostriecin (10 6 M) for
either (A) 2 h (triangles) or 4 h (circles) or (B) 24 h. After incubation, each set of
cells was washed and incubated for 10min with isoprenaline (1010–105 M)
before challenge with anti-IgE (1:300) for 25min to induce histamine release.
Values expressed as % inhibition of control histamine release, that is, in (A) 38
[± 8]% (in buffer studies), 40 [± 5]% (in 2-h fostriecin studies), and 37 [± 6]% (in
4-h fostriecin studies), or in (B) 26 [± 3]% (in 24-h buffer studies) and 30 [± 4]%
(in 24-h fostriecin studies) following treatments with buffer or fostriecin. Values
shown are means ± SEM, n¼ 5/regimen. All values were significantly different (p
< 0.05) vs. respective controls.
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Figure 3. Effect of fostriecin on salbutamol inhibition of histamine release from
HLMC. Cells were incubated (A) 4 h or (B) 24 h with buffer (control) or fostriecin
(10 6 M). After incubation, cells were washed and then incubated with salbuta-
mol (1010–105 M) before challenge with anti-IgE (1:300) for 25min to induce
histamine release. Results are expressed as % inhibition of control histamine
release, that is, in (A) 26 [± 6]% (in buffer studies) and 23 [± 5]% (in fostriecin
studies), and in (B) 40 [± 4]% (in buffer studies) and 37 [± 5]% (in fostriecin stud-
ies) following treatments with buffer or fostriecin. Values are means ± SEM,
n¼ 6/regimen.
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was 40 ± 4% relative to release by cells stimulated with anti-IgE
alone). The effects of fostriecin on desensitization were hard to
discern since fostriecin pretreatment significantly (p < .001) atte-
nuated inhibitory effects from the subsequent salbutamol
re-exposure before anti-IgE administration.
Effects on desensitization
The effects of fostriecin on recovery from isoprenaline-induced
desensitization were investigated (Figure 6.). Longer (24 h) treat-
ment of the mast cells with isoprenaline (106 M) caused a 80%
reduction in the maximal response to isoprenaline. If cells were
allowed to recover from this treatment for 24 h, there was  50%
recovery in responses. However, if recovery was done in the pres-
ence of fostriecin (106 M), the extent of recovery was not as
great. Though the data suggested fostriecin impeded recovery, it
seemed here fostriecin reduced the maximal response to isopren-
aline – complicating data interpretation.
A similar trend was observed when the effects of fostriecin
on recovery from salbutamol-induced desensitization were investi-
gated (Figure 7). Longer (24 h) treatment of mast cells with salbu-
tamol (106 M) caused an 87% reduction in the maximal response
to salbutamol. If the cells were allowed to recover from this treat-
ment for 24 h, then there was an 57% recovery in the response
to salbutamol. However, if recovery was performed in the presence
of fostriecin (106 M), then the extent of recovery was not as
great. However, fostriecin alone reduced the maximal response to
salbutamol making interpretation of the data difficult.
Discussion
As part of the intracellular process leading to mast cell activation,
the phosphorylation state of key substrates is likely to be import-
ant. G protein-dependent and arrestin-dependent functions of
many G-protein-coupled receptors (GPCR) can be dissociated
pharmacologically by ligands that exhibit functional selectivity or
a “bias” favoring one pathway or another. Thus, differential cou-
pling of receptors to G protein- and arrestin-based pathways is
one of many mechanisms underlying ligand-directed signaling.
Whereas conventional GPCR agonists and antagonists are
believed to activate or inhibit all aspects of signaling equally,
“biased agonists” have a potential to change the signal output of
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Figure 4. Effect of fostriecin on isoprenaline-mediated functional desensitization.
Cells were incubated (24 h) j without (control) or ^ with isoprenaline (106 M)
or  fostriecin (106 M) or  fostriecin and isoprenaline combined. After incu-
bation, cells were washed and then incubated with isoprenaline (1010–105 M)
for 10min before challenge with anti-IgE (1:300) to induce histamine release.
Values are expressed as % inhibition of control histamine release, that is, 46
[± 2]% (in buffer studies), 44 [± 3]% (in isoprenaline studies), 42 [± 3]% (in fostrie-
cin studies) and 39 [± 2]% (in fostriecinþ isoprenaline studies) following treat-
ment with buffer, isoprenaline, fostriecin, or isoprenalineþ fostriecin. Values
shown are means ± SEM, n¼ 7/regimen.
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Figure 5. Effect of fostriecin on salbutamol-mediated functional desensitization.
HLMC were incubated (24 h) jwithout (control) or  with either salbutamol
(106 M), or  fostriecin (106 M) or · salbutamolþ fostriecin. After incubation,cells were washed extensively and then incubated with salbutamol (1010
–105 M) for 10min before challenge with anti-IgE (1:300) to induce histamine
release. Values are expressed as % inhibition of control histamine release, that is,
40 [± 4]% (in buffer studies), 37 [± 6]% (in salbutamol studies), 37 [± 5]% (in fos-
triecin studies), and 36 [± 7]% (in fostriecinþ salbutamol studies) after treatment
with buffer, salbutamol, fostriecin, or salbutamolþ fostriecin. Values shown are
means ± SEM, n¼ 8/regimen.
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Figure 6. Influence of fostriecin on recovery from desensitization. Cells were
incubated (24 h) without (control) or with isoprenaline (106 M) and then washed
and incubated without or with isoprenaline (106 M) and with or without fostrie-
cin (106 M) for a further 24 h. The cells were then extensively washed and incu-
bated with isoprenaline (1010–105 M) for 10min before challenge with anti-IgE
(1:300) to induce histamine release. Values are expressed as % inhibition of the
control histamine release, that is, in (A) 31 [±3]% (square), 40 [± 3]% (closed cir-
cle), 36 [± 4]% (triangle) and in (B) 31 [± 3]% (square), 35 [± 4]% (diamond) and
38 [± 4]% (open circle). Split panels are provided for clarity. Values shown are
means ± SEM, n¼ 10/regimen.
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a GPCR, thereby controlling not only the quantity but also the
quality of efficacy.
Desensitization can be induced by challenge of immune cells
like mast cells with IgE-dependent signals. During desensitiza-
tion, phosphorylated receptors uncouple from G-proteins and
can be targeted for internalization. Once internalized, the recep-
tors may either be degraded or recycled to the cell surface. With
respect to recycling, it appears that dephosphorylation of the
receptor, by a PP2A-like phosphatase, is involved in ensuring
receptor re-expression. Our previous studies (Peirce et al. 1997)
provided a framework for the study here to determine the role, if
any, of PP2A in desensitization/re-sensitization of mast cells.
Those studies (and later ones) had shown that mast cells
expressed PP2A but that inhibition of PP2A with the highly
selective inhibitor fostriecin had no effect on IgE-mediated hista-
mine release (Bastan et al. 2001). Thus, the effects of fostriecin
on b2-adrenoceptor-driven responses in mast cells were investi-
gated in the present study.
Initially, the effects of pretreatment (up to 24 h) of the mast
cells with fostriecin on the subsequent activity of b-agonists were
investigated. Pretreatments of up to 24 h with fostriecin alone
had no effect on IgE-mediated histamine release. Shorter pre-
treatments had little effect on the activity of isoprenaline and sal-
butamol to inhibit histamine release. However, after 24-h
treatment with fostriecin, there was a modest reduction in
potency of isoprenaline and a rather more substantial attenuation
in ability of salbutamol to inhibit histamine release. These find-
ings suggested that there was low-level constitutive phosphoryl-
ation of b2-adrenoceptors by some kinases in the cells. Inhibition
of PP2A by fostriecin prevented dephosphorylation of the
receptors; the implications from this was that as levels of phos-
phorylated receptors increased in a time-related manner, an
increased number of receptors were thus made nonusable. The
higher efficacy agonist isoprenaline tolerates this loss in receptors
more so than the partial agonist salbutamol. Indeed, this effect of
fostriecin on the responses of isoprenaline and salbutamol was
reminiscent of studies by Drury et al. (1998) in which propor-
tions of mast cell b2-adrenoceptors were inactivated with the
irreversible antagonist bromo-acetyl-alprenolol methane (BAAM).
Treatments with BAAM affected the response of mast cells to sal-
butamol to a greater degree that responses to isoprenaline.
Although this conjecture is speculative, these data suggested
PP2A could regulate b2-adrenoceptors in mast cells.
Effects of fostriecin on functional desensitization and resensi-
tization of b2-adrenoceptor-mediated responses in mast cells
were also investigated. However, as treatment with fostriecin
appeared to exert some residual effects on responses to isopren-
aline and especially salbutamol, these studies proved difficult to
interpret. There was some suggestion that fostriecin acted to pre-
vent recovery from desensitization. Presumably, the mechanism
involved in resensitization would be the dephosphorylation of
phosphorylated receptors. Inhibition of PP2A, with fostriecin,
would prevent the dephosphorylation and thereby impair the
recovery at b2-adrenoceptor-mediated responses.
Some studies were also performed with okadaic acid (OA)
that inhibits PP2A at low concentrations and PP1 at higher con-
centrations (Takai et al. 1995; Favre 1997). When used at a con-
centration (30 nM) that should be selective for PP2A and that
had no effect by itself on histamine release, OA enhanced the
isoprenaline-induced desensitization in mast cells. Again, these
data suggest that PP2A has a role in limiting desensitization.
Despite the inconclusive nature of some of these experiments,
collectively, these data suggest that PP2A has an important role
in regulating mast cell b2-adrenoceptors. Further work will estab-
lish whether this is indeed the case.
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